Idorsia Ltd
SIX:IDIA
Idorsia Ltd
EPS (Diluted)
Idorsia Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Idorsia Ltd
SIX:IDIA
|
EPS (Diluted)
CHf0
|
CAGR 3-Years
53%
|
CAGR 5-Years
30%
|
CAGR 10-Years
N/A
|
|
|
ADC Therapeutics SA
NYSE:ADCT
|
EPS (Diluted)
-$1
|
CAGR 3-Years
17%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
EPS (Diluted)
-$6
|
CAGR 3-Years
8%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-26%
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
EPS (Diluted)
CHf2
|
CAGR 3-Years
42%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
EPS (Diluted)
CHf0
|
CAGR 3-Years
21%
|
CAGR 5-Years
20%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
EPS (Diluted)
-CHf1
|
CAGR 3-Years
33%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
Glance View
Idorsia Ltd. operates as a biopharmaceutical firm which focuses on discovery, development and commercialization of innovative medicines for unmet medical needs. The company is headquartered in Allschwil, Basel-Landschaft. The company went IPO on 2017-06-16. The firm will have a diverse clinical development pipeline comprising several compounds being investigated in multiple therapeutic areas, including central nervous system disorders, cardiovascular disorders, immunological disorders and orphan diseases. The firm's development compounds target a number of different diseases such as: Resistant Hypertension, Systemic lupus erythematosus, Chronic insomnia and Fabry disease, among others.
See Also
What is Idorsia Ltd's EPS (Diluted)?
EPS (Diluted)
-0.5
CHF
Based on the financial report for Sep 30, 2025, Idorsia Ltd's EPS (Diluted) amounts to -0.5 CHF.
What is Idorsia Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 5Y
30%
Over the last year, the EPS (Diluted) growth was 67%. The average annual EPS (Diluted) growth rates for Idorsia Ltd have been 53% over the past three years , 30% over the past five years .
